| Literature DB >> 18451139 |
Björn Hackanson1, Kristi L Bennett, Romulo M Brena, Jinmai Jiang, Rainer Claus, Shih-Shih Chen, Nadya Blagitko-Dorfs, Katie Maharry, Susan P Whitman, Thomas D Schmittgen, Michael Lübbert, Guido Marcucci, Clara D Bloomfield, Christoph Plass.
Abstract
Functional loss of CCAAT/enhancer binding protein alpha (C/EBP alpha), a master regulatory transcription factor in the hematopoietic system, can result in a differentiation block in granulopoiesis and thus contribute to leukemic transformation. Here, we show the effect of epigenetic aberrations in regulating C/EBP alpha expression in acute myeloid leukemia (AML). Comprehensive DNA methylation analyses of the CpG island of C/EBP alpha identified a densely methylated upstream promoter region in 51% of AML patients. Aberrant DNA methylation was strongly associated with two generally prognostically favorable cytogenetic subgroups: inv(16) and t(15;17). Surprisingly, while epigenetic treatment increased C/EBP alpha mRNA levels in vitro, C/EBP alpha protein levels decreased. Using a computational microRNA (miRNA) prediction approach and functional studies, we show that C/EBP alpha mRNA is a target for miRNA-124a. This miRNA is frequently silenced by epigenetic mechanisms in leukemia cell lines, becomes up-regulated after epigenetic treatment, and targets the C/EBP alpha 3' untranslated region. In this way, C/EBP alpha protein expression is reduced in a posttranscriptional manner. Our results indicate that epigenetic alterations of C/EBP alpha are a frequent event in AML and that epigenetic treatment can result in down-regulation of a key hematopoietic transcription factor.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18451139 DOI: 10.1158/0008-5472.CAN-08-0483
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701